以载体为导向的免疫力和VRP-srRNA抗瘤疫苗的增强能力
Xingru Ma1, Robert D Marek1, Susannah Gammell2
1Department of Pathology, Duke University, Durham, NC, USA.
NPJ vaccines
|March 17, 2026
概括
病毒复制粒子 (VRP) 自复制RNA疫苗具有强效,但可能因载体免疫性而面临重复剂量限制. 研究表明,先前的VRP暴露可以减少随后的疫苗反应.
科学领域:
- 疫苗学 疫苗学 疫苗学
- 免疫学 免疫学 免疫学
- 在RNA治疗方面,RNA疗法.
背景情况:
- 通过病毒复制品 (VRPs) 提供的自我复制RNA (srRNA) 疫苗具有强大的免疫性.
- 然而,以VRP为基础的疫苗在短时间间隔内重复施用可能会引起抗载体免疫力,可能会影响疗效.
- 了解这些载体反应对于优化srRNA疫苗策略至关重要.
研究的目的:
- 研究重复剂量和先前暴露对VRP-srRNA疫苗免疫性的影响.
- 描述VRP-srRNA疫苗接种产生的免疫反应,包括中和抗体和T细胞活性.
- 通过优化疫苗接种计划,探索维持或增强免疫反应的策略.
主要方法:
- 在VRP-srRNA接种疫苗后分析患者样本和小鼠模型.
- 对VRP中和抗体的测量.
- 对针对病毒复制酶的T细胞反应的评估.
- 评估转基因免疫在短时间间隔的多次剂量后.
- 测试先前VRP暴露对异种VRP疫苗反应的影响.
主要成果:
- 接种VRP-srRNA疫苗诱导了VRP中和抗体和T细胞对复制酶蛋白的反应.
- 在两周间隔的第三剂疫苗剂量显示,对小鼠转基因免疫的额外益处很小.
- 之前对VRP的暴露减少了对编码不同转基因的后续VRP疫苗的免疫反应.
- 有证据表明,抗载体免疫反应在重复或连续剂量后限制了疫苗的疗效.
结论:
- 短时间内重复接种VRP-srRNA疫苗可能会因抗载体免疫的发展而受到限制.
- 之前暴露于VRP可能会损害以后基于VRP的疫苗的免疫性.
- 优化剂量计划或异质的主要提升策略可能是必要的,以克服载体反应和保持疫苗的有效性.
更多相关视频
08:10Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
Published on: November 28, 2018
9.2K
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
17.9K
相关概念视频
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Vaccines
1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Rous Sarcoma Virus (RSV) and Cancer
6.6K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.6K
Rous Sarcoma Virus (RSV) and Cancer
5.9K
5.9K
Vaccinations
53.3K
Overview
53.3K
Immune Response Against Viral Pathogens
2.4K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.4K
